BeiGene ups offering to a whopping $750M; Celgene backing $475M raise for Agios; Avastin copycat OK'd for Europe
→ In a demonstration of its popularity, BeiGene $BGNE has priced its public offering at $750 million — quite a bit more than the $650 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
